PE Fund Investments
Denmark's Novozymes acquires 60% stake in Synergia Life Sciences for $150-M
Bagsvaerd (Denmark)-based Novozymes has acquired a 60% stake in Mumbai-based Synergia Life Sciences for USD 150 million. The remaining 40% is to be acquired by 2025. Synergia, a player in the field of spore probiotics and vitamin K2-7, has a global footprint, including three production sites in India with 2021 pro forma sales of Danish Krone (DKK) 150 million (USD 22.86 million) and EBITDA/EBIT margins well above Novozymes'. It is a key supplier to Microbiome Labs. Post deal, the founders of Synergia will continue to be actively involved in the business. The deal is projected to help Novozymes strengthen and accelerate its position in human health and functional foods, adding strong developing and manufacturing capabilities in spore probiotics and vitamin K2-7.
From the Venture Intelligence PE-VC Deal Database: In Oct-15, Synergia Life Sciences had raised $6-M from India Life Sciences Fund. (Subscribers to the database can login to view the valuation, deal structuring and other transaction details.)
Want to receive such news items in your inbox? Click Here to sign up for a trial.
